Best change in target lesions in response-evaluable patients per IRC. Response-evaluable patients (n = 83) were those with a target lesion(s) assessed at baseline and with at least 1 on-study time point with all baseline target lesion(s) assessed. Negative values indicate maximum tumor reduction; positive values indicate minimum tumor increase; best change is based on evaluable target lesion measurements up to progression or start of subsequent therapy. Dashed horizontal line indicates the 50% reduction consistent with a response per revised 2007 International Working Group criteria.